Cargando…

ABCC4 Is a Determinant of Cytarabine‐Induced Cytotoxicity and Myelosuppression

Resistance to cytarabine remains a major challenge in the treatment of acute myeloid leukemia (AML). Based on previous studies implicating ABCC4/MRP4 in the transport of nucleosides, we hypothesized that cytarabine is sensitive to ABCC4‐mediated efflux, thereby decreasing its cytotoxic response agai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drenberg, CD, Hu, S, Li, L, Buelow, DR, Orwick, SJ, Gibson, AA, Schuetz, JD, Sparreboom, A, Baker, SD
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905720/ https://www.ncbi.nlm.nih.gov/pubmed/26842729 http://dx.doi.org/10.1111/cts.12366

Ejemplares similares

Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia
por: Jost, Felix, et al.
Publicado: (2019)

DNA Methylation‐Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia
por: Buelow, Daelynn R., et al.
Publicado: (2020)

Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine
por: Adema, Auke D, et al.
Publicado: (2014)

Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice
por: Anderson, Jason T., et al.
Publicado: (2019)

Undetected Severe Fetal Myelosuppression following Administration of High-Dose Cytarabine for Acute Myeloid Leukemia: Is More Frequent Surveillance Necessary?
por: Parrott, Jessica, et al.
Publicado: (2017)

Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51
por: Xie, Chengzhi, et al.
Publicado: (2013)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Translational Modeling of Drug‐Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor
por: Collins, TA, et al.
Publicado: (2017)

Roles of ABCC1 and ABCC4 in Proliferation and Migration of Breast Cancer Cell Lines
por: Low, Floren G., et al.
Publicado: (2020)

Determinants of Myelosuppression in the Treatment of Non‐small Cell Lung Cancer with Cisplatin‐containing Chemotherapy
por: Matsui, Kaoru, et al.
Publicado: (1996)

A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML
por: Drenberg, Christina D., et al.
Publicado: (2019)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Myelosuppression by sunitinib is flt-3 genotype dependent
por: van Erp, N P, et al.
Publicado: (2010)

Sleeping through the storm: Preventing myelosuppression with quizartinib
por: Taylor, Samuel J., et al.
Publicado: (2017)

Antineoplastics: Myelosuppression and COVID-19: case report
Publicado: (2020)

Palbociclib: Myelosuppression and gastrointestinal reactions: case report
Publicado: (2022)

Rational design of a new cytarabine-based prodrug for highly efficient oral delivery of cytarabine
por: Zhang, Jing, et al.
Publicado: (2018)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
por: Nishi, Rie, et al.
Publicado: (2020)

Clinicopathological Impact of ABCC1/MRP1 and ABCC4/MRP4 in Epithelial Ovarian Carcinoma
por: Bagnoli, Marina, et al.
Publicado: (2013)

Cytarabine-Induced Encephalitis
por: Lenfant, Christine, et al.
Publicado: (2021)

Promotion of Myelopoiesis in Myelosuppressed Mice by Ganoderma lucidum Polysaccharides
por: Zhu, Xiao-Ling, et al.
Publicado: (2012)

Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk
por: Nguyen, Christine M., et al.
Publicado: (2011)

Multiple drugs: Aseptic Meningitis and myelosuppression: case report
Publicado: (2022)

ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux
por: Henderson, Michelle J., et al.
Publicado: (2011)

Multidrug transporter MRP4/ABCC4 as a key determinant of pancreatic cancer aggressiveness
por: Sahores, A., et al.
Publicado: (2020)

Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide
por: Bins, S, et al.
Publicado: (2017)

Complications of MRSA Treatment: Linezolid-induced Myelosuppression Presenting with Pancytopenia
por: Gorchynski, Julie, et al.
Publicado: (2008)

Hematopoietic Effects of Paeoniflorin and Albiflorin on Radiotherapy-Induced Myelosuppression Mice
por: Zhu, Yingli, et al.
Publicado: (2016)

New Insights on Glucosylceramide Synthase in Cancer Drug Resistance and Myelosuppression
por: Gupta, Vineet, et al.
Publicado: (2013)

TGFβ restores hematopoietic homeostasis after myelosuppressive chemotherapy
por: Brenet, Fabienne, et al.
Publicado: (2013)

Lurasidone Induced Thrombocytopenia: Is it a Signal of Drug Induced Myelosuppression?
por: Rafi, Mohammad, et al.
Publicado: (2018)

An Early Myelosuppression in the Acute Mouse Sepsis Is Partly Outcome-Dependent
por: Skirecki, Tomasz, et al.
Publicado: (2021)

Ayurveda-based Botanicals as Therapeutic Adjuvants in Paclitaxel-induced Myelosuppression
por: Saggam, Akash, et al.
Publicado: (2022)

Myelosuppression Rates with Administration of Nafcillin with and without Rifampin in Pediatric Patients
por: Kuriakose, Jolly, et al.
Publicado: (2022)

Predictive Model of Chemotherapy-Induced Myelosuppression for Patients with Esophageal Cancer
por: Zheng, Ziming, et al.
Publicado: (2022)

ABCC9 Is Downregulated and Prone to Microsatellite Instability on ABCC9tetra in Canine Breast Cancer
por: Hao, Pan, et al.
Publicado: (2022)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Cytotoxic Marine Alkaloid 3,10-Dibromofascaplysin Induces Apoptosis and Synergizes with Cytarabine Resulting in Leukemia Cell Death
por: Spirin, Pavel, et al.
Publicado: (2021)

Galectin-9 has non-apoptotic cytotoxic activity toward acute myeloid leukemia independent of cytarabine resistance
por: Choukrani, Ghizlane, et al.
Publicado: (2023)

Founder genetic variants of ABCC4 and ABCC11 in the Japanese population are not associated with the development of subacute myelo‐optico‐neuropathy (SMON)
por: Matsumoto, Hideki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_93l6m53u0jfj3kf12i53j9f1p7